Bridging The Distance To Large-Scale GMP Manufacturing Of Viral Vectors

Over the past decade, gene therapy has made significant advancements, garnering multiple recent approvals. In several of these commercial processes for viral vector manufacturing, iCELLis™ bioreactors are utilized. The industry is constantly evolving, and the technology designed to expedite the development of life-changing medical treatments for patients has evolved in tandem.

In this webinar, AGC Biologics shares its journey to the successful implementation of iCELLis™ bioreactors and how they have used this technology to establish and support its AAV and lentivirus platforms.